Earnings Call · Q3 FY2024·2024-11-14

Q3 24EPS +33.33%·Rev n/aQ2 24EPS +69.43%·Rev n/aQ1 24EPS -24.29%·Rev n/aQ4 23EPS +4.40%·Rev n/a⚠ consensus missing

BioXcel Therapeutics, Inc. BTAI

Vimal Mehta — Chief Executive Officer

Richard Steinhart — Chief Financial Officer

−15.9%1d on move date−15.3% vs SPY3d−6.3%5d−5.0%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more BTAI calls or request research access.

More BTAI calls Browse calls Request research access